GlassScriptPhysician profile
Harleen Kaur
NPI 1922267012
$863.15
in general payments reported to CMS, 2019-2025
16 companies · $427 in 2025
The $427 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $59.98 · 2023: $218 · 2024: $159 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $136.18 | 2023-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $111.13 | 2025 | Livdelzi |
| Astrazeneca Pharmaceuticals LP | $93.17 | 2023 | |
| Ardelyx, INC. | $74.57 | 2024-2025 | Ibsrela |
| Abbvie INC. | $65.79 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.82 | 2023-2025 | Xifaxan |
| Edwards Lifesciences Corporation | $59.98 | 2020 | |
| Sanofi Pasteur INC. | $53.36 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $52.39 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $48.80 | 2025 | Jardiance |
| Celltrion USA INC. | $25.11 | 2024 | Vegzelma |
| Janssen Biotech, INC. | $18.31 | 2025 | Tremfya |
| Otsuka America Pharmaceutical, INC. | $16.67 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $15.37 | 2023 | Entyvio |
| Glaxosmithkline, LLC. | $14.81 | 2024 | Shingrix, Arexvy |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.69 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harleen Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.